ABB $22.24

down -0.20


19/6/2013 04:19 PM  |  NYSE : ABB  |  Industries : Manufacturing / Other Electrical Equipment and Component Manufacturing
Last Trade: 22.24
Trade Time: Jun 19 4:06 PM Eastern Daylight Time
Change: -0.20 (-0.89 %)
Prev Close: 22.44
Open: 22.69
Bid: 22.25
Ask: 22.31
Quotes displayed are delayed by 15 minutes. Market data is provided by Telvent DTN
Get Trend Analysis Icon Get ABB Trend Analysis - it has outperformed the S&P 500 by 17%

ETF Alternatives



People viewing ABB also viewed: , , , ,

Competitors

Ticker Name Volume % Change
PWDY POWERDYNE INTERNATIONAL 1.0K +0.98%
CEFLF CERAMIC FUEL CELLS 4.0K +0.21%
CSGH CHINA SUN GP HIGH-TECH 55.0K +0.15%
CETC CLEAN ENVIRO TECH CORP. NEW CO 122.2K +0.12%
APWC ASIA PACIFIC WIRE & CABLE 2.0K +0.07%
View All

ABB Stock Analysis

  1. Data on BMY/ AbbVie's elotuzumab - Analyst Blog

    (SNTS,BMY,CELG,ABBV )
    Bristol-Myers and partner AbbVie presented data on elotuzumab from a phase II study.
  2.

    Abbott Progresses with Absorb in Japan - Analyst Blog

    (ABT,ABBV,BAXS,ATRC )
    Abbott Labs (ABT) recently announced that it has initiated a randomized controlled study in Japan to evaluate Absorb, its bioresorbable vascular scaffold (BVS) device, in patients suffering from coronary artery disease (CAD).

  3. New Data on UCB's Cimzia - Analyst Blog

    (UCBJF,ABBV,SNTS,JNJ )
    UCB presented new data from the RAPID-PsA study and RAPID-axSpA study on Cimzia at the European League Against Rheumatism (EULAR) Congress.
  4.

    Positive Data on Incyte/LLY's Baricitinib - Analyst Blog

    (LLY,INCY,JAZZ,ABBV )
    Incyte and Eli Lilly announced positive results from a study on baricitinib.
  5.

    Encouraging Data from Bristol-Myers - Analyst Blog

    (BMY,BIIB,JAZZ,ABBV )
    Bristol-Myers presented encouraging long-term data from a phase IIIb study on Orencia.
  6.

    Label Expansion for Roche's RoActemra - Analyst Blog

    (RHHBY,ABBV,SNTS,UCBJF )
    Roche announced that it obtained European Medicines Agency (EMA) approval for the label expansion of its rheumatoid arthritis (RA) drug RoActemra.
Free Reports
  1.

    FREE Futures Trading Package

    The Great Free Give a Way To Serious Futures Traders! Valued at $390!
  2.

    3 Stocks Peter Lynch Would Buy Today

    This new special report identifies 3 stocks based on Lynch’s market-trouncing strategy that could more than double in the next 12 months.
  3.

    View the Portfolios of the Worlds Top Investors, FREE!

    Learn from Warren Buffett, George Soros and More!
Marketplace
Trading Center